Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more
Oramed Pharmaceuticals Inc - Asset Resilience Ratio
Oramed Pharmaceuticals Inc (ORMP) has an Asset Resilience Ratio of 37.42% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Oramed Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Oramed Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $82.51 Million | 37.42% |
| Total Liquid Assets | $82.51 Million | 37.42% |
Asset Resilience Insights
- Very High Liquidity: Oramed Pharmaceuticals Inc maintains exceptional liquid asset reserves at 37.42% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oramed Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Oramed Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Oramed Pharmaceuticals Inc (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Oramed Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 56.36% | $87.51 Million | $155.28 Million | -13.01pp |
| 2023-12-31 | 69.37% | $152.99 Million | $220.55 Million | -1.94pp |
| 2022-12-31 | 71.30% | $115.26 Million | $161.64 Million | +58.10pp |
| 2021-12-31 | 13.20% | $16.89 Million | $128.00 Million | -32.96pp |
| 2020-12-31 | 46.16% | $20.60 Million | $44.63 Million | -37.36pp |
| 2019-12-31 | 83.53% | $28.95 Million | $34.66 Million | +29.80pp |
| 2018-12-31 | 53.73% | $25.47 Million | $47.40 Million | +12.01pp |
| 2017-12-31 | 41.73% | $16.15 Million | $38.71 Million | -21.57pp |
| 2016-12-31 | 63.29% | $27.11 Million | $42.83 Million | +10.11pp |
| 2015-12-31 | 53.18% | $14.02 Million | $26.35 Million | -36.39pp |
| 2014-12-31 | 89.57% | $19.53 Million | $21.80 Million | +17.94pp |
| 2013-12-31 | 71.63% | $6.20 Million | $8.66 Million | +67.84pp |
| 2012-12-31 | 3.78% | $200.31K | $5.29 Million | -5.11pp |
| 2011-12-31 | 8.89% | $384.56K | $4.33 Million | +2.00pp |
| 2010-12-31 | 6.89% | $100.00K | $1.45 Million | -23.77pp |
| 2009-12-31 | 30.66% | $1.00 Million | $3.26 Million | -18.88pp |
| 2008-12-31 | 49.54% | $2.73 Million | $5.51 Million | -- |